ALZAMEND NEURO, INC. Proceeds from Issuance or Sale of Equity
ALZAMEND NEURO, INC. (ALZN) reported Proceeds from Issuance or Sale of Equity of $2.88 million for the 1-month period ending 2021-06-17, per its 10-K filed 2023-07-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2023-07-27
- 2021-06-17: Proceeds from Issuance or Sale of Equity 1 month $2.88M.
| Period end | Proceeds from Issuance or Sale of Equity 1 month |
|---|---|
| 2021-06-17 | $2.88M 10-K · filed 2023-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |